AP2005003368A0 - PyrazoloÄ1,5-AÜÄ1,3,5Ütriazine derivatives as cannabinoid receptor ligands. - Google Patents

PyrazoloÄ1,5-AÜÄ1,3,5Ütriazine derivatives as cannabinoid receptor ligands.

Info

Publication number: AP2005003368A0
Authority: AP; ARIPO
Prior art keywords: aüä1; derivatives; receptor ligands; cannabinoid receptor; cannabinoid
Prior art date: 2003-02-06

Application number

AP2005003368A

Other languages

English (en)

Inventor

Andrew Griffith David

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-06

Filing date

2004-01-26

Publication date

2005-09-30

2004-01-26 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-09-30 Publication of AP2005003368A0 publication Critical patent/AP2005003368A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pregnancy & Childbirth (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AP2005003368A 2003-02-06 2004-01-26 PyrazoloÄ1,5-AÜÄ1,3,5Ütriazine derivatives as cannabinoid receptor ligands. AP2005003368A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US44572803P	2003-02-06	2003-02-06
PCT/IB2004/000269 WO2004069837A1 (fr)	2003-02-06	2004-01-26	Derives de pyrazolo[1,5-a][1,3,5]triazine en tant que ligands de recepteur cannabinoide

Publications (1)

Publication Number	Publication Date
AP2005003368A0 true AP2005003368A0 (en)	2005-09-30

Family

ID=32851000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2005003368A AP2005003368A0 (en)	2003-02-06	2004-01-26	PyrazoloÄ1,5-AÜÄ1,3,5Ütriazine derivatives as cannabinoid receptor ligands.

Country Status (29)

Country	Link
US (1)	US7329658B2 (fr)
EP (1)	EP1592691A1 (fr)
JP (1)	JP4018736B2 (fr)
KR (1)	KR20050099531A (fr)
CN (1)	CN1768061A (fr)
AP (1)	AP2005003368A0 (fr)
AR (1)	AR043038A1 (fr)
AU (1)	AU2004209447A1 (fr)
BR (1)	BRPI0406957A (fr)
CA (1)	CA2513409A1 (fr)
CL (1)	CL2004000182A1 (fr)
CR (1)	CR7932A (fr)
EA (1)	EA200501253A1 (fr)
EC (1)	ECSP055945A (fr)
GT (1)	GT200400013A (fr)
HR (1)	HRP20050659A2 (fr)
IS (1)	IS7936A (fr)
MA (1)	MA27652A1 (fr)
MX (1)	MXPA05007562A (fr)
NL (1)	NL1025404C2 (fr)
NO (1)	NO20054082L (fr)
OA (1)	OA12980A (fr)
PE (1)	PE20040946A1 (fr)
PL (1)	PL379009A1 (fr)
TN (1)	TNSN05190A1 (fr)
TW (1)	TWI260223B (fr)
UY (1)	UY28178A1 (fr)
WO (1)	WO2004069837A1 (fr)
ZA (1)	ZA200506255B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2494091C (fr) *	2002-08-02	2011-02-01	Richard B. Toupence	Derives furo [2,3-b\| pyridine substitues
US7176210B2 (en)	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) *	2003-04-23	2004-10-28	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US7268133B2 (en)	2003-04-23	2007-09-11	Pfizer, Inc. Patent Department	Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) *	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
WO2004099157A1 (fr) *	2003-05-07	2004-11-18	Pfizer Products Inc.	Ligands de recepteurs cannabinoides et leurs applications
US20040224962A1 (en) *	2003-05-09	2004-11-11	Pfizer Inc	Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7232823B2 (en) *	2003-06-09	2007-06-19	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
US20050026983A1 (en) *	2003-07-30	2005-02-03	Pfizer Inc	Imidazole compounds and uses thereof
US20050043327A1 (en) *	2003-08-21	2005-02-24	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7151097B2 (en) *	2003-11-07	2006-12-19	Pfizer Inc.	Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
WO2005049615A1 (fr) *	2003-11-21	2005-06-02	Pfizer Products Inc.	Derives de pyrazolo[1,5-a][1,3,5]triazin-4-one en tant qu'antagonistes des recepteurs cb1
US7649002B2 (en)	2004-02-04	2010-01-19	Pfizer Inc	(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
PA8660701A1 (es)	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
WO2006129193A2 (fr) *	2005-05-27	2006-12-07	Pfizer Products Inc.	Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale
US7923465B2 (en)	2005-06-02	2011-04-12	Glenmark Pharmaceuticals S.A.	Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
PL1902034T3 (pl)	2005-06-02	2011-09-30	Glenmark Pharmaceuticals Sa	Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
WO2006131807A1 (fr) *	2005-06-06	2006-12-14	Pfizer Products Inc.	Preparation de derives de pyrazole 3-amino-4,5-disubstitues
JP2008545009A (ja)	2005-06-30	2008-12-11	プロシディオン・リミテッド	Ｇｐｃｒアゴニスト
JP4847275B2 (ja) *	2005-10-21	2011-12-28	田辺三菱製薬株式会社	ピラゾロ［１，５−ａ］ピリミジン化合物
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
AU2007219236B2 (en)	2006-02-23	2012-06-21	Pfizer Limited	Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
TWI419889B (zh) *	2006-07-05	2013-12-21	Mitsubishi Tanabe Pharma Corp	吡唑并〔１，５-ａ〕嘧啶化合物
EP2084127A1 (fr)	2006-11-13	2009-08-05	Pfizer Products Inc.	Dérivés diaryle, dipyridinyle et aryl-pyridinyle et leurs utilisations
KR100808241B1 (ko) *	2006-11-21	2008-03-03	윤성화	Ｃｂ1에 길항 활성을 갖는 1ｈ-파이라졸-3-옥심카바메이트화합물 유도체
ATE547394T1 (de)	2006-12-01	2012-03-15	Bristol Myers Squibb Co	N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
CL2008000017A1 (es)	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0700122D0 (en)	2007-01-04	2007-02-14	Prosidion Ltd	GPCR agonists
EA016507B1 (ru)	2007-01-04	2012-05-30	Прозидион Лимитед	Пиперидиновые агонисты gpcr
ATE523507T1 (de)	2007-01-04	2011-09-15	Prosidion Ltd	Piperidin-gpcr-agonisten
PE20081659A1 (es)	2007-01-04	2008-10-24	Prosidion Ltd	Agonistas de gpcr
PE20090142A1 (es) *	2007-04-11	2009-02-19	Merck & Co Inc	Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
JP4837701B2 (ja) *	2007-04-20	2011-12-14	田辺三菱製薬株式会社	医薬組成物
GB0720390D0 (en)	2007-10-18	2007-11-28	Prosidion Ltd	G-Protein coupled receptor agonists
GB0720389D0 (en)	2007-10-18	2008-11-12	Prosidion Ltd	G-Protein Coupled Receptor Agonists
SG157299A1 (en) *	2008-05-09	2009-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
AU2009278838B2 (en)	2008-08-06	2013-07-25	Pfizer Limited	Diazepine and diazocane compounds as MC4 agonists
WO2012138945A1 (fr) *	2011-04-08	2012-10-11	Aestus Therapeutics, Inc.	Procédés de traitement de la schizophrénie avec des inhibiteurs à base de dérivés du pyrazole de tgf-bêta
US8871754B2 (en)	2012-11-19	2014-10-28	Irm Llc	Compounds and compositions for the treatment of parasitic diseases
DK2925757T3 (en)	2012-11-19	2018-01-15	Novartis Ag	Compounds and compositions for the treatment of parasitic diseases
CA3089159A1 (fr) *	2018-02-06	2019-08-15	Jiangsu Hengrui Medicine Co., Ltd.	Derive de pyrazolo[1,5-a][1,3,5]triazine-2-amine, son procede de preparation et son utilisation medicale
CN110551133A (zh) *	2019-07-23	2019-12-10	上海合全药业股份有限公司	叔丁基-5-(羟甲基)-7-氧杂-2-氮杂螺[3.5]壬烷-2-甲酸基酯的制法
CN112574214B (zh) *	2019-07-30	2021-09-28	杭州阿诺生物医药科技有限公司	腺苷受体拮抗剂的制备方法
TWI794742B (zh)	2020-02-18	2023-03-01	美商基利科學股份有限公司	抗病毒化合物
TWI775313B (zh)	2020-02-18	2022-08-21	美商基利科學股份有限公司	抗病毒化合物
AR121356A1 (es)	2020-02-18	2022-05-11	Gilead Sciences Inc	Compuestos antivirales
ES3028915T3 (en)	2021-04-16	2025-06-20	Gilead Sciences Inc	Methods of preparing carbanucleosides using amides
EP4387977A1 (fr)	2021-08-18	2024-06-26	Gilead Sciences, Inc.	Composés phospholipidiques et leurs procédés de production et d'utilisation

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US574491A (en) *		1897-01-05		Brake-beam
US3865824A (en)	1972-03-07	1975-02-11	Icn Pharmaceuticals	2-Aryl-7-substituted pyrazolo {8 1,5{i a{b {9 1,3,5-triazines
US3910907A (en)	1973-07-09	1975-10-07	Icn Pharmaceuticals	Pyrazolo(1,5-a)-1,3,5-triazines
US3995039A (en)	1975-05-27	1976-11-30	Merck & Co., Inc.	Pyrazolo [1,5-a] [1,3,5] triazines
CH635587A5 (fr)	1978-01-09	1983-04-15	Aron Sa	Derives amines de pyrazolo (1,5-a) s.triazine, therapeutiquement actifs et leurs procedes de preparation.
US4767858A (en)	1985-06-06	1988-08-30	Biomeasure, Incorporated	Anti-arthritic pyrazolo-triazine derivatives
US4734414A (en)	1985-06-06	1988-03-29	Biomeasure, Inc.	Anti-inflammatory and anti-arthritic pyrazolo-[1,5-a]-1,3,5-triazine derivatives, compositions, and method of use therefor
GB8613591D0 (en)	1986-06-04	1986-07-09	Roussel Lab Ltd	Chemical compounds
EP0268554B1 (fr)	1986-10-22	1991-12-27	Ciba-Geigy Ag	Dérivés d'acide diphényl-1,5-pyrazol-3-carbonique pour la protection de plantes de culture
US4824834A (en)	1986-10-31	1989-04-25	Otsuka Pharmaceutical Company, Limited	Pyrazolotriazine compounds
US5051518A (en)	1987-05-29	1991-09-24	Ortho Pharmaceutical Corporation	Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
AU611437B2 (en)	1987-05-29	1991-06-13	Ortho Pharmaceutical Corporation	Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
JPH0276880A (ja)	1988-06-16	1990-03-16	Sankyo Co Ltd	悪液質改善治療剤
CA1330079C (fr)	1988-10-13	1994-06-07	Michihiko Tsujitani	Derive pyrrolo-(3,2-e)pyrazolo(1,5-a)pyrimidine et medicament en contenant
JP2691317B2 (ja)	1989-08-25	1997-12-17	株式会社大塚製薬工場	４―ヒドロキシ―８―（３―低級アルコキシ―４―フェニルスルフィニルフェニル）ピラゾロ〔１，５―ａ〕―１，３，５―トリアジン光学活性体の塩類及びその製造方法
PH27357A (en)	1989-09-22	1993-06-21	Fujisawa Pharmaceutical Co	Pyrazole derivatives and pharmaceutical compositions comprising the same
EP0459702A1 (fr)	1990-05-29	1991-12-04	Zeneca Limited	Dérivés d'azoles
US5356894A (en)	1990-05-29	1994-10-18	Rodney Peter W	Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
FR2665898B1 (fr)	1990-08-20	1994-03-11	Sanofi	Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
KR927003595A (ko)	1990-10-09	1992-12-18	오츠카 아키히코	피리미딘 유도체, 이의 제조방법 및 안드로겐 저해제
GB9111131D0 (en)	1991-05-23	1991-07-17	Ici Plc	Heterocyclic compounds
GB9111130D0 (en)	1991-05-23	1991-07-17	Ici Plc	Azole derivatives
GB9125002D0 (en)	1991-11-25	1992-01-22	Ici Plc	Azole derivatives
FR2692575B1 (fr)	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5571813A (en)	1993-06-10	1996-11-05	Beiersdorf-Lilly Gmbh	Fused pyrimidine compounds and their use as pharmaceuticals
FR2714057B1 (fr)	1993-12-17	1996-03-08	Sanofi Elf	Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en)	1994-07-15	1997-01-21	Eli Lilly And Company	Cannabinoid receptor antagonists
FR2741621B1 (fr)	1995-11-23	1998-02-13	Sanofi Sa	Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr)	1995-12-08	1999-10-22	Sanofi Sa	Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
EA006626B1 (ru)	1996-07-24	2006-02-24	Дюпон Фармасьютикалз Компани	Азолопиримидины, фармацевтическая композиция и способ лечения
US6124289A (en)	1996-07-24	2000-09-26	Dupont Pharmaceuticals Co.	Azolo triazines and pyrimidines
US6191131B1 (en)	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6313124B1 (en)	1997-07-23	2001-11-06	Dupont Pharmaceuticals Company	Tetrazine bicyclic compounds
US6060478A (en)	1996-07-24	2000-05-09	Dupont Pharmaceuticals	Azolo triazines and pyrimidines
ES2213892T3 (es)	1997-01-21	2004-09-01	Smithkline Beecham Corporation	Nuevos moduladores del receptor de canabinoides.
FR2758723B1 (fr)	1997-01-28	1999-04-23	Sanofi Sa	Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2761266B1 (fr)	1997-03-28	1999-07-02	Sanofi Sa	Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
IL137019A (en)	1998-01-28	2010-11-30	Du Pont Pharm Co	2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
US6194410B1 (en)	1998-03-11	2001-02-27	Hoffman-La Roche Inc.	Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6509338B1 (en)	1998-06-22	2003-01-21	Bristol-Myers Squibb Company	Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
FR2783246B1 (fr)	1998-09-11	2000-11-17	Aventis Pharma Sa	Derives d'azetidine, leur preparation et les medicaments les contenant
KR100652994B1 (ko)	1998-09-11	2006-11-30	아방티 파르마 소시에테 아노님	아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제
FR2789079B3 (fr)	1999-02-01	2001-03-02	Sanofi Synthelabo	Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
CN1377355A (zh)	1999-09-30	2002-10-30	纽罗杰有限公司	氨基取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
AU7738100A (en)	1999-09-30	2001-04-30	Neurogen Corporation	Certain alkylene diamine-substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
FR2799124B1 (fr)	1999-10-01	2004-08-13	Sanofi Synthelabo	Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
MXPA02005101A (es)	1999-10-18	2003-09-25	Alexipharma Inc	Derivados de indol canabimimeticos.
AU780572B2 (en)	1999-10-18	2005-04-07	University Of Connecticut, The	Pyrazole derivatives as cannabinoid receptor antagonists
FR2800375B1 (fr)	1999-11-03	2004-07-23	Sanofi Synthelabo	Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
FR2800372B1 (fr)	1999-11-03	2001-12-07	Sanofi Synthelabo	Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
AU2001233144A1 (en)	2000-01-31	2001-08-07	The University Of Kentucky Research Foundation	Triazines as appetite suppressor
FR2804604B1 (fr)	2000-02-09	2005-05-27	Sanofi Synthelabo	Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6653304B2 (en)	2000-02-11	2003-11-25	Bristol-Myers Squibb Co.	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6566356B2 (en)	2000-03-03	2003-05-20	Aventis Pharma S.A.	Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6355631B1 (en)	2000-03-03	2002-03-12	Aventis Pharma S.A.	Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6479479B2 (en)	2000-03-03	2002-11-12	Aventis Pharma S.A.	Azetidine derivatives, their preparation and pharmaceutical compositions containing them
ES2272449T3 (es)	2000-03-23	2007-05-01	Solvay Pharmaceuticals B.V.	Derivados de 4,5-dihidro-1h-pirazol con actividad antagosnista de cb-1.
FR2809621B1 (fr)	2000-05-12	2002-09-06	Sanofi Synthelabo	Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
US20020019421A1 (en)	2000-07-05	2002-02-14	Roni Biberman	Compositions and therapy for substance addiction
US20020091114A1 (en)	2000-10-04	2002-07-11	Odile Piot-Grosjean	Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
FR2814678B1 (fr) *	2000-10-04	2002-12-20	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
KR100843281B1 (ko)	2000-12-28	2008-07-09	오노 야꾸힝 고교 가부시키가이샤	삼환식 복소환 유도체 화합물 및 그 화합물을 유효성분으로 하는 의약
ATE355102T1 (de)	2001-03-13	2006-03-15	Bristol Myers Squibb Pharma Co	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6- methoxypyrid-3-yl) pyrazolo- 1,5-aö-1,3,5-triazin,seine enantiomeren und pharmazeutisch annehmbare salze als corticotropin-releasing-factor-rezeptor-ligande
KR100846614B1 (ko)	2001-03-22	2008-07-16	솔베이 파마슈티칼스 비. 브이	Ｃｂ1-길항 활성을 갖는 4,5-디하이드로-1ｈ-피라졸 유도체
ITMI20011483A1 (it)	2001-07-11	2003-01-11	Res & Innovation Soc Coop A R	Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
AU2002319627A1 (en)	2001-07-20	2003-03-03	Merck And Co., Inc.	Substituted imidazoles as cannabinoid receptor modulators
FR2829028B1 (fr)	2001-08-29	2004-12-17	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
FR2829027A1 (fr)	2001-08-29	2003-03-07	Aventis Pharma Sa	Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
EP1421077A4 (fr)	2001-08-31	2004-11-17	Univ Connecticut	Nouveaux analogues de pyrazole agissant sur les recepteurs cannabinoides
TWI231757B (en)	2001-09-21	2005-05-01	Solvay Pharm Bv	1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
CA2456606C (fr)	2001-09-21	2010-01-26	Solvay Pharmaceuticals B.V.	Derives 4,5-dihydro-1h-pyrazole presentant une activite antagoniste a cb1
US6974810B2 (en)	2001-09-21	2005-12-13	Solvay Pharmaceuticals B.V.	4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
US6509367B1 (en)	2001-09-22	2003-01-21	Virginia Commonwealth University	Pyrazole cannabinoid agonist and antagonists
ATE311386T1 (de)	2001-09-24	2005-12-15	Bayer Pharmaceuticals Corp	Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit
JP2005532982A (ja)	2001-09-24	2005-11-04	バイエル・フアーマシユーチカルズ・コーポレーシヨン	肥満の処置のためのピロール誘導体の製造及び使用
UY27450A1 (es)	2001-09-24	2003-04-30	Bayer Corp	Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
SE0104332D0 (sv)	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
SE0104330D0 (sv)	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
US20030139386A1 (en)	2001-12-21	2003-07-24	Sophie Cote	Pharmaceutical compositions based on azetidine derivatives
EP1482794A1 (fr)	2002-03-06	2004-12-08	Merck & Co., Inc.	Methode de traitement ou de prevention de l'obesite
AU2003217712A1 (en)	2002-03-07	2003-09-22	Smithkline Beecham Corporation	Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
NZ534757A (en)	2002-03-12	2006-07-28	Merck & Co Inc	Substituted amides
AR038966A1 (es)	2002-03-18	2005-02-02	Solvay Pharm Bv	Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
CA2479618A1 (fr)	2002-03-26	2003-10-09	William K. Hagmann	Amides spirocycliques en tant que modulateurs du recepteur cannabinoide
ES2192494B1 (es)	2002-03-27	2005-02-16	Consejo Superior De Investigaciones Cientificas	Derivados de 1,2,4-triazol con propiedades cannabinoides.
US7271266B2 (en)	2002-03-28	2007-09-18	Merck & Co., Inc.	Substituted 2,3-diphenyl pyridines
FR2837706A1 (fr)	2002-03-28	2003-10-03	Sanofi Synthelabo	Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
CA2480856A1 (fr)	2002-04-05	2003-10-23	Merck & Co., Inc.	Arylamides substituee
FR2838439B1 (fr)	2002-04-11	2005-05-20	Sanofi Synthelabo	Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
WO2003086288A2 (fr)	2002-04-12	2003-10-23	Merck & Co., Inc.	Amides bicycliques
US6825209B2 (en)	2002-04-15	2004-11-30	Research Triangle Institute	Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ATE365740T1 (de)	2002-05-10	2007-07-15	Smithkline Beecham Corp	Substituierte pyrazolopyrimidine
CN100366207C (zh)	2002-08-02	2008-02-06	华沙整形外科股份有限公司	用于照明手术空间的系统和技术
UA80295C2 (en)	2002-09-06	2007-09-10	Biogen Inc	Pyrazolopyridines and using the same
AU2003267728A1 (en)	2002-10-18	2004-05-04	Pfizer Products Inc.	Cannabinoid receptor ligands and uses thereof
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
US7247628B2 (en)	2002-12-12	2007-07-24	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
TWI290500B (en) *	2004-12-14	2007-12-01	Arima Optoelectronics Corp	Laser dicing apparatus for a silicon wafer and dicing method thereof

2004
- 2004-01-21 US US10/763,105 patent/US7329658B2/en not_active Expired - Fee Related
- 2004-01-26 CA CA002513409A patent/CA2513409A1/fr not_active Abandoned
- 2004-01-26 WO PCT/IB2004/000269 patent/WO2004069837A1/fr not_active Ceased
- 2004-01-26 EA EA200501253A patent/EA200501253A1/ru unknown
- 2004-01-26 AP AP2005003368A patent/AP2005003368A0/xx unknown
- 2004-01-26 EP EP04705138A patent/EP1592691A1/fr not_active Withdrawn
- 2004-01-26 KR KR1020057014432A patent/KR20050099531A/ko not_active Abandoned
- 2004-01-26 MX MXPA05007562A patent/MXPA05007562A/es unknown
- 2004-01-26 AU AU2004209447A patent/AU2004209447A1/en not_active Abandoned
- 2004-01-26 PL PL379009A patent/PL379009A1/pl not_active Application Discontinuation
- 2004-01-26 JP JP2006500314A patent/JP4018736B2/ja not_active Expired - Fee Related
- 2004-01-26 BR BR0406957-9A patent/BRPI0406957A/pt not_active IP Right Cessation
- 2004-01-26 HR HR20050659A patent/HRP20050659A2/hr not_active Application Discontinuation
- 2004-01-26 OA OA1200500215A patent/OA12980A/en unknown
- 2004-01-26 CN CNA2004800091255A patent/CN1768061A/zh active Pending
- 2004-02-03 CL CL200400182A patent/CL2004000182A1/es unknown
- 2004-02-03 PE PE2004000124A patent/PE20040946A1/es not_active Application Discontinuation
- 2004-02-04 UY UY28178A patent/UY28178A1/es not_active Application Discontinuation
- 2004-02-04 NL NL1025404A patent/NL1025404C2/nl not_active IP Right Cessation
- 2004-02-05 AR ARP040100365A patent/AR043038A1/es unknown
- 2004-02-05 TW TW093102638A patent/TWI260223B/zh not_active IP Right Cessation
- 2004-02-06 GT GT200400013A patent/GT200400013A/es unknown
2005
- 2005-07-11 IS IS7936A patent/IS7936A/is unknown
- 2005-08-02 EC EC2005005945A patent/ECSP055945A/es unknown
- 2005-08-04 ZA ZA200506255A patent/ZA200506255B/en unknown
- 2005-08-04 CR CR7932A patent/CR7932A/es not_active Application Discontinuation
- 2005-08-05 MA MA28421A patent/MA27652A1/fr unknown
- 2005-08-05 TN TNP2005000190A patent/TNSN05190A1/fr unknown
- 2005-09-02 NO NO20054082A patent/NO20054082L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
MXPA05007562A (es)	2005-09-21
TNSN05190A1 (fr)	2007-06-11
EP1592691A1 (fr)	2005-11-09
BRPI0406957A (pt)	2006-01-03
AU2004209447A8 (en)	2004-08-19
EA200501253A1 (ru)	2006-02-24
AR043038A1 (es)	2005-07-13
AU2004209447A1 (en)	2004-08-19
CR7932A (es)	2005-09-16
NL1025404C2 (nl)	2005-03-14
CA2513409A1 (fr)	2004-08-19
NL1025404A1 (nl)	2004-08-09
TWI260223B (en)	2006-08-21
IS7936A (is)	2005-07-11
ZA200506255B (en)	2006-05-31
PE20040946A1 (es)	2005-01-01
TW200423942A (en)	2004-11-16
CL2004000182A1 (es)	2005-01-07
US20040157839A1 (en)	2004-08-12
MA27652A1 (fr)	2005-12-01
KR20050099531A (ko)	2005-10-13
OA12980A (en)	2006-10-13
GT200400013A (es)	2004-12-16
US7329658B2 (en)	2008-02-12
PL379009A1 (pl)	2006-06-26
WO2004069837A1 (fr)	2004-08-19
ECSP055945A (es)	2006-01-27
NO20054082L (no)	2005-11-04
NO20054082D0 (no)	2005-09-02
CN1768061A (zh)	2006-05-03
UY28178A1 (es)	2004-09-30
HRP20050659A2 (en)	2006-02-28
JP2006517203A (ja)	2006-07-20
JP4018736B2 (ja)	2007-12-05

Publication	Publication Date	Title
AP2005003368A0 (en)	2005-09-30	PyrazoloÄ1,5-AÜÄ1,3,5Ütriazine derivatives as cannabinoid receptor ligands.
MXPA03007078A (es)	2003-11-18	Ligandos del receptor de canabinoide.
HRP20050053A2 (en)	2005-04-30	1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
ZA200606974B (en)	2008-04-30	Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
AP2005003426A0 (en)	2005-12-31	Cannabinoid receptor ligands and uses thereof.
AP2005003427A0 (en)	2005-12-31	Cannabinoid receptor ligands and uses thereof.
AP2005003466A0 (en)	2005-12-31	Cannabinoid receptor ligands and uses thereof.
EG23424A (en)	2005-07-12	Fungicidal azo-carboxamide derivatives.
PL377295A1 (pl)	2006-01-23	Pochodne 4,5-diarylotiazolu jako ligandy CB-1
SI1699795T1 (sl)	2007-10-31	Substituirani 8-piri(mi)dinil-dihidrospiro-(cikloalkilamin)pirimido(1,2a) pirimidin-6-onski derivati
ZA200309521B (en)	2004-09-28	Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives.
ZA200500170B (en)	2006-02-22	Indole-3-sulphur derivatives.
ZA200409339B (en)	2006-02-22	Novel benzimidazole derivatives.
AU2003257172A1 (en)	2004-02-25	Cannabinoid receptor ligands
ZA200400926B (en)	2005-02-04	Diamine derivatives.
EG25273A (en)	2011-12-04	Substituted dihydroquinazolines.
ZA200506744B (en)	2006-06-28	PyrazoloÄ1,5-AÜpyrimidine derivatives
MXPA03008140A (es)	2003-12-12	Amidas de acido benzofuran-2-carboxilico sustituidas.
MA27306A1 (fr)	2005-05-02	Ligands des recepteurs de la melanocortine.
MXPA03009002A (es)	2004-02-12	5-halogeno-6-fenil-7-fluoroalquilamino-triazolopirimidinas.
EG23207A (en)	2004-07-31	Novel fungicidal compositions based on propamocarsand pyridylmethylbenzamide derivatives.
AU2003294449A1 (en)	2004-06-18	Cannabinoid receptor ligands
IL182538A0 (en)	2007-09-20	1,5-diheterocycle-1h-triazole derivative
ZA200408029B (en)	2005-10-06	Novel 1,3,5-triazine derivatives as ligands for human adenosine-A3 receptors.
MXPA03008394A (es)	2004-01-29	Derivados de biuretano.